118 related articles for article (PubMed ID: 35963316)
1. Harmaline downregulates angiogenesis markers and suppresses the growth of 4T1 breast cancer cells in vivo and in vitro.
Rashidi M; Mahmoudian E; Mirzaei S; Mazloomi SN; Bazi A; Azadeh H; Mozaffari M
Chem Biol Interact; 2022 Sep; 365():110087. PubMed ID: 35963316
[TBL] [Abstract][Full Text] [Related]
2. Hesperidin suppressed metastasis, angiogenesis and tumour growth in Balb/c mice model of breast cancer.
Shakiba E; Bazi A; Ghasemi H; Eshaghi-Gorji R; Mehdipour SA; Nikfar B; Rashidi M; Mirzaei S
J Cell Mol Med; 2023 Sep; 27(18):2756-2769. PubMed ID: 37581480
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
4. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.
Tarasenko N; Cutts SM; Phillips DR; Inbal A; Nudelman A; Kessler-Icekson G; Rephaeli A
PLoS One; 2012; 7(2):e31393. PubMed ID: 22384017
[TBL] [Abstract][Full Text] [Related]
5. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
6. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of Auraptene in 4T1 tumor-bearing Balb/c mice.
Shiran MR; Amani D; Ajami A; Jalalpourroodsari M; Khalizadeh M; Rashidi M
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):245-252. PubMed ID: 33675195
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
9. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the effects of crab derived exosomes and doxorubicin in 2 & 3-dimensional in vivo models of breast cancer.
Rezakhani L; Rahmati S; Ghasemi S; Alizadeh M; Alizadeh A
Chem Phys Lipids; 2022 Mar; 243():105179. PubMed ID: 35150707
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
13. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
14. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
15. Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice.
Amani D; Shakiba E; Motaghi E; Alipanah H; Jalalpourroodsari M; Rashidi M
Horm Mol Biol Clin Investig; 2021 Sep; 43(1):71-79. PubMed ID: 34496167
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
Yahuafai J; Asai T; Oku N; Siripong P
Biol Pharm Bull; 2018; 41(7):1103-1106. PubMed ID: 29962406
[TBL] [Abstract][Full Text] [Related]
19. Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway.
Hajra S; Patra AR; Basu A; Saha P; Bhattacharya S
Chem Biol Interact; 2018 Jun; 290():19-36. PubMed ID: 29775573
[TBL] [Abstract][Full Text] [Related]
20. Bioreducible PAA-g-PEG graft micelles with high doxorubicin loading for targeted antitumor effect against mouse breast carcinoma.
Sun Y; Zou W; Bian S; Huang Y; Tan Y; Liang J; Fan Y; Zhang X
Biomaterials; 2013 Sep; 34(28):6818-28. PubMed ID: 23764117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]